NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence

Gallagher C, Emmanuel OO · Ageing Research Reviews

The field's most complete audit. Rodent studies frequently showed metabolic, mitochondrial and functional gains. In humans, oral NR and NMN consistently hit their biochemical target — circulating and cellular NAD+ rose — and were well tolerated over weeks to months, but effects on functional, metabolic, vascular and other healthspan outcomes were heterogeneous and often null or endpoint-specific. No outcomes trial of intravenous NAD+ for anti-ageing exists.

Population

113 intervention studies (33 human, 28 of them randomised; 80 rodent), January 2010 to October 2025

Intervention

Oral or parenteral NAD+ precursors including NR and NMN

Comparator

Placebo or control

Limitations

Narrative synthesis without pooled estimates, because the endpoints are too heterogeneous to combine. No joint or cartilage endpoint appears anywhere in the 113 studies.